Eli Lilly (LLY) traded sharply lower (about -3.6%) after weekly prescription data signaled a wobble in momentum for its obesity franchise. The key datapoint investors reacted to was a week-over-week decline in prescriptions for Lilly’s injectable weight-loss drug Zepbound, while a competing product, Novo Nordisk’s Wegovy, showed an increase—rekindling concerns that the competitive battle in obesity could tighten in the near term.

Weekly GLP-1 script checks are a high-frequency read on demand, access, and share shifts in a category where expectations are extremely high and valuations are sensitive to small changes in trajectory. Even with signs that overall GLP-1 demand remains resilient, today’s reaction suggests the market is prioritizing relative momentum—especially whether Zepbound can keep outpacing alternatives as supply, coverage, and patient switching dynamics evolve.

Investors will likely keep monitoring the next few weekly script reports to see whether the Zepbound dip was a one-week noise event or an early signal of slowing growth. The next major catalyst is Lilly’s upcoming quarterly report date (April 30, 2026), where management commentary on obesity and diabetes demand, access trends, and launch execution for newer offerings will be scrutinized for confirmation or pushback on today’s market-share worries.